Targeted Therapy With Immunoconjugates for Multiple Myeloma

Targeted Therapy With Immunoconjugates for Multiple Myeloma

The introduction of proteasome inhibitors (PI) and immunomodulatory drugs (IMiD) has markedly increased the survival of multiple myeloma (MM) patients. Also, the unconjugated monoclonal antibodies (mAb) daratumumab (anti-CD38) and elotuzumab (anti-SLAMF7) have revolutionized MM treatment given their...

Full description

Bibliographic Details
Main Authors: Wassilis S. C. Bruins, Sonja Zweegman, Tuna Mutis, Niels W. C. J. van de Donk
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-06-01
Series:Frontiers in Immunology
Subjects:
multiple myeloma
immunoconjugates
antibody-drug conjugates
immunotoxins
immunocytokines
radioimmunoconjugates
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01155/full

Internet

https://www.frontiersin.org/article/10.3389/fimmu.2020.01155/full

Similar Items